



## SUNSTONE LSV INVEST II ApS

Store Strandstræde 18 A, st.  
1255 København K  
CVR No. 30575261

## Annual report 2023

The Annual General Meeting adopted the annual report on 24.04.2024

---

**Merete Lundbye Møller**  
Chairwoman of the General Meeting

# Contents

Entity details	2
Statement by Management	3
Independent auditor's compilation report	4
Management commentary	5
Income statement for 2023	6
Balance sheet at 31.12.2023	7
Statement of changes in equity for 2023	9
Notes	10
Accounting policies	11

# Entity details

## Entity

SUNSTONE LSV INVEST II ApS

Store Strandstræde 18 A, st.

1255 København K

Business Registration No.: 30575261

Registered office: Copenhagen

Financial year: 01.01.2023 - 31.12.2023

## Executive Board

Sten Verland

Søren Lemonius

Merete Lundbye Møller

## Auditors

Deloitte Statsautoriseret Revisionspartnerselskab

Weidekampsgade 6

2300 Copenhagen S

# Statement by Management

The Executive Board has today considered and approved the annual report of SUNSTONE LSV INVEST II ApS for the financial year 01.01.2023 - 31.12.2023.

The annual report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Entity's financial position at 31.12.2023 and of the results of its operations for the financial year 01.01.2023 - 31.12.2023.

We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.

We confirm that the requirements for not auditing the financial statements are met.

We recommend the annual report for adoption at the Annual General Meeting.

Copenhagen, 24.04.2024

## Executive Board

**Sten Verland**

**Søren Lemonius**

**Merete Lundbye Møller**

# Independent auditor's compilation report

## To Management of SUNSTONE LSV INVEST II ApS

We have compiled the financial statements of SUNSTONE LSV INVEST II ApS for the financial year 01.01.2023 - 31.12.2023 based on the Entity's bookkeeping records and other information Management has provided.

These financial statements comprise the income statement, balance sheet, statement of changes in equity, notes and a summary of significant accounting policies.

We performed this compilation engagement in accordance with ISRS 4410, Compilation Engagements.

We have applied our expertise in accounting and financial reporting to assist Management in the preparation and presentation of these financial statements in accordance with the Danish Financial Statements Act. We have complied with relevant provisions of the Danish Public Accountants Act and the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code), including principles of integrity, objectivity, professional competence and due care.

These financial statements and the accuracy and completeness of the information used to compile the financial statements are Management's responsibility.

Since a compilation engagement is not an assurance engagement, we are not required to verify the accuracy or completeness of the disclosures Management provided to us to compile these financial statements. Accordingly, we do not express an audit opinion or a review conclusion about whether the financial statements have been prepared in accordance with the Danish Financial Statements Act.

Copenhagen, 24.04.2024

### **Deloitte**

Statsautoriseret Revisionspartnerselskab  
CVR No. 33963556

### **Rikke Frydkjær Hansen**

State Authorised Public Accountant  
Identification No (MNE) mne46616

# Management commentary

## Primary activities

The primary activity for the Company is to hold shares in Sunstone Life Science Ventures Fund II K/S.

The Company has had no employees during the year.

## Events after the balance sheet date

No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.

# Income statement for 2023

	Notes	2023 DKK'000	2022 DKK '000
Other external expenses		(12)	(10)
<b>Gross profit/loss</b>		<b>(12)</b>	<b>(10)</b>
Income from financial assets		105	0
Other financial income		4	0
Impairment losses on financial assets		(464)	(4,190)
Other financial expenses		(1)	(3)
<b>Profit/loss for the year</b>		<b>(368)</b>	<b>(4,203)</b>
<b>Proposed distribution of profit and loss:</b>			
Retained earnings		(368)	(4,203)
<b>Proposed distribution of profit and loss</b>		<b>(368)</b>	<b>(4,203)</b>

# Balance sheet at 31.12.2023

## Assets

	Notes	2023 DKK'000	2022 DKK'000
Other investments		213	677
<b>Financial assets</b>	1	<b>213</b>	<b>677</b>
<b>Fixed assets</b>		<b>213</b>	<b>677</b>
<b>Cash</b>		<b>175</b>	<b>78</b>
<b>Current assets</b>		<b>175</b>	<b>78</b>
<b>Assets</b>		<b>388</b>	<b>755</b>



**Equity and liabilities**

	<b>Notes</b>	<b>2023</b> <b>DKK'000</b>	<b>2022</b> <b>DKK'000</b>
Contributed capital	2	3,779	3,779
Retained earnings		(3,402)	(3,034)
<b>Equity</b>		<b>377</b>	<b>745</b>
Other payables		11	10
<b>Current liabilities other than provisions</b>		<b>11</b>	<b>10</b>
<b>Liabilities other than provisions</b>		<b>11</b>	<b>10</b>
<b>Equity and liabilities</b>		<b>388</b>	<b>755</b>
Contingent assets	3		
Contingent liabilities	4		

# Statement of changes in equity for 2023

	<b>Contributed capital DKK'000</b>	<b>Retained earnings DKK'000</b>	<b>Total DKK'000</b>
Equity beginning of year	3,779	(3,034)	745
Profit/loss for the year	0	(368)	(368)
<b>Equity end of year</b>	<b>3,779</b>	<b>(3,402)</b>	<b>377</b>

# Notes

## 1 Financial assets

	<b>Other investments DKK'000</b>
Cost beginning of year	6,107
<b>Cost end of year</b>	<b>6,107</b>
Impairment losses beginning of year	(5,430)
Impairment losses for the year	(464)
<b>Impairment losses end of year</b>	<b>(5,894)</b>
<b>Carrying amount end of year</b>	<b>213</b>

Other investments comprise: Sunstone Life Science Ventures Fund II K/S, Copenhagen, 0.95%.

## 2 Share capital

Share capital consists of 3,778,876 shares at DKK 1.

## 3 Contingent assets

The Company has an unrecognised tax asset which amounts to DKK 1.214 thousand.

## 4 Contingent liabilities

The Company participates in a Danish joint taxation arrangement where SUNSTONE LSV INVEST II HOLDING ApS serves as the administration company. According to the joint taxation provisions of the Danish Corporation Tax Act, the Company is therefore liable for income taxes etc for the jointly taxed entities, and for obligations, if any, relating to the withholding of tax on interest, royalties and dividend for the jointly taxed entities. The jointly taxed entities' total known net liability under the joint taxation arrangement is disclosed in the administration company's financial statements.

The Company has no guarantees or contingent liabilities, but has an outstanding commitment of DKK 31 thousand.

# Accounting policies

## Reporting class

This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class B enterprises with addition of a few provisions for reporting class C.

The accounting policies applied to these financial statements are consistent with those applied last year.

The annual report is presented in DKK 1,000.

## Going concern

The Company has lost over half of its contributed capital. The capital is expected to be reestablished through future profit in Sunstone Life Science Ventures Fund II K/S.

Sunstone Life Science Ventures A/S has issued a comfort letter to support the operation and financing throughout the next year.

## Recognition and measurement

Assets are recognised in the balance sheet when it is probable as a result of a prior event that future economic benefits will flow to the Entity, and the value of the asset can be measured reliably.

Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the value of the liability can be measured reliably.

On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial recognition is effected as described below for each financial statement item.

Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and measurement.

Income is recognised in the income statement when earned, whereas costs are recognised by the amounts attributable to this financial year.

## Income statement

### Other external expenses

Other external expenses include expenses relating to administration.

### Income from other fixed asset investments

Income from other fixed asset investments comprises gains in the form of interest, dividends, etc on fixed asset investments which are not investments in group enterprises or associates.

### Other financial income

Other financial income comprises interest income.

**Impairment losses on financial assets**

Impairment losses on financial assets comprise impairment losses on financial assets which are not measured at fair value on a current basis.

**Other financial expenses**

Other financial expenses comprise interest expenses

**Balance sheet****Other investments**

Other investments is measured at cost. Where the recoverable amount is lower than cost, other investments is written down to the recoverable amount.

**Cash**

Cash comprises bank deposits.

**Other financial liabilities**

Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.